Wolverine Trading’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-26,000
Closed -$235K 5399
2024
Q1
$235K Buy
+26,000
New +$253K ﹤0.01% 3619
2023
Q4
Sell
-21,300
Closed -$171K 5411
2023
Q3
$171K Buy
+21,300
New +$177K ﹤0.01% 3813
2021
Q4
Sell
-21,900
Closed -$250K 7097
2021
Q3
$250K Buy
21,900
+1,800
+9% +$24.8K ﹤0.01% 4990
2021
Q2
$365K Sell
20,100
-500
-2% -$8.04K ﹤0.01% 4140
2021
Q1
$295K Buy
20,600
+7,600
+58% +$110K ﹤0.01% 4492
2020
Q4
$160K Sell
13,000
-6,300
-33% -$87.8K ﹤0.01% 4334
2020
Q3
$224K Buy
19,300
+15,475
+405% +$134K ﹤0.01% 3747
2020
Q2
$38K Sell
3,825
-3,375
-47% -$31K ﹤0.01% 4361
2020
Q1
$53K Buy
7,200
+600
+9% +$5.2K ﹤0.01% 4243
2019
Q4
$57K Buy
6,600
+775
+13% +$4.35K ﹤0.01% 4432
2019
Q3
$35K Sell
5,825
-4,875
-46% -$39.4K ﹤0.01% 4110
2019
Q2
$178K Buy
10,700
+1,500
+16% +$26.1K ﹤0.01% 3774
2019
Q1
$154K Buy
9,200
+5,025
+120% +$72.3K ﹤0.01% 3978
2018
Q4
$50K Buy
+4,175
New +$84.5K ﹤0.01% 4175

Other funds holding MRNS

Wolverine Trading's MRNS Position: Q2 2024 in Review

Wolverine Trading sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 11,165 shares — an estimated $101K sold.

Wolverine Trading first reported a position in MRNS in Q4 2018 and held it in 11 quarters. The position peaked at $261K in Q1 2021. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • Wolverine Trading reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • Wolverine Trading sold 11,165 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $101K.
  • Wolverine Trading first reported a position in Marinus Pharmaceuticals, Inc in Q4 2018 and held it in 11 quarters.
  • Wolverine Trading's Marinus Pharmaceuticals, Inc position peaked at $261K in Q1 2021.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on Wolverine Trading's 13F filing for Q2 2024, filed 14 Aug 2024.